Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
VEDANTA BIOSCIENCES, INC. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, meaning each pending matter is being reviewed by a different individual. This distribution shows that the company's current pharmaceutical filings are not consolidated under a single examiner, requiring the applicant to manage two separate review styles simultaneously.
The portfolio is active across 2 distinct art units. This matches the count of 2 distinct examiners, suggesting that each examiner is operating in a different art unit. ARIANI, KADE is the busiest examiner with 1 pending action, which accounts for half of the 2 pending office actions. This structure requires the company to navigate two different regulatory environments and two different examiner review styles simultaneously. For a practitioner, the success of the 2 pending office actions depends on addressing the specific requirements of 2 distinct art units and 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 74.9% | +32.1% |
| IANNUZO, NATALIE NMN | 1 | 11.9% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 26d |
| 18574232 | METHODS OF COLONIZING A MICROBIOME, TREATING AND/OR PREVENTING INFLAMMATORY BOWEL DISEASE AND GRAFT VERSUS HOST DISEASE | ARIANI, KADE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574232 | METHODS OF COLONIZING A MICROBIOME, TREATING AND/OR PREVENTING INFLAMMATORY BOWEL DISEASE AND GRAFT VERSUS HOST DISEASE | ARIANI, KADE | 1651 | — | Non-Final OA | — | Pending | Dec 26, 2023 |
| 17633930 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | 26d | Pending | Feb 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVEDANTA BIOSCIENCES, INC. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Kade Ariani has the most, with 1 of VEDANTA BIOSCIENCES, INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.